Kisspeptin-10
EmergingNeuropeptide family (RFamide)
Kisspeptin-10 is a decapeptide fragment of the kisspeptin protein, encoded by the KISS1 gene. It has been studied in reproductive endocrinology research for its effects on GnRH neuron activation and its role in puberty onset and reproductive function regulation. Published research has examined its receptor (GPR54/KISS1R) signaling and pulsatile secretion patterns. RaysunPeptide supplies Kisspeptin-10 for qualified research and laboratory applications.
Mechanism of Action
Binds to GPR54/KISS1R receptors on hypothalamic GnRH neurons, triggering pulsatile GnRH release, which stimulates pituitary LH/FSH secretion and gonadal steroid production.
Key Benefits
Molecular Data
Dosing Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Gonadotropin stimulation | 100-200mcg | Single dose or 2-3x weekly | SubQ |
| Fertility support | 0.4-1.0 nmol/kg (50-150mcg) | As directed by physician | SubQ (KP-54) |
| Sexual function (clinical) | 1 nmol/kg/h | 75-minute IV infusion | IV infusion |
Research Indications
Reproductive
Restores reproductive hormone secretion in functional or congenital cases by stimulating dormant GnRH axis.
Triggers oocyte maturation with 45% live birth rate and zero severe OHSS cases; safer than hCG.
Restores reproductive hormone pulsatility in women with hypothalamic amenorrhea.
Sexual Function
Modulates sexual brain processing; increases penile tumescence by 56% vs placebo.
Modulates sexual and attraction brain processing; increases self-reported sexiness.
Metabolic
Preclinical evidence suggests influence on energy expenditure and activity levels.
Peptide Interactions
Kisspeptin stimulates GnRH release; works upstream in reproductive axis.
Serves as potentially safer alternative for IVF ovulation triggering.
Restores natural testosterone production through LH stimulation.
Kisspeptin function modulated by sex steroids in feedback loops.
What to Expect
Side Effects & Safety
Common (Generally Mild)
- •Minimal acute side effects reported
- •Potential mild cardiovascular effects
Stop Signs (Seek Medical Attention)
- ⚠Ovarian hyperstimulation signs: severe pelvic pain, bloating, nausea
- ⚠Chest pain or cardiovascular symptoms
- ⚠Severe headaches or visual disturbances
- ⚠Persistent injection site reactions
Contraindications
- ✕Not recommended during pregnancy or breastfeeding
- ✕Caution with cardiovascular disease history
- ✕Daily dosing causes receptor desensitization
Quality Checklist
Good Signs ✓
- White, fluffy powder; proper freeze-drying indicated
- Clear solution after reconstitution; no particles or cloudiness
- Protected from light in amber/opaque vials
Warning Signs !
- Slight compaction acceptable if dissolves completely with gentle swirling
Bad Signs ✕
- Discoloration or yellowing indicates oxidation/degradation
- Cloudy after reconstitution indicates degradation or contamination
References
32 men completed trial. Kisspeptin-54 IV (1 nmol/kg/h for 75 min) significantly modulated sexual brain processing and increased penile tumescence by up to 56% vs placebo. Potential as first pharmacological treatment for male HSDD.
View on PubMed →Double-masked, placebo-controlled, 2-way crossover trial in women with HSDD. Kisspeptin modulated sexual and facial attraction brain processing, with hippocampal activation correlating with distress and reduced sexual aversion.
View on PubMed →Live birth rates of 45% overall per transfer; 62% at optimal 9.6 nmol/kg dose. Zero cases of moderate, severe, or critical OHSS. Oocyte maturation in 95% of women.
View on PubMed →Intranasal kisspeptin-54 (12.8 nmol/kg) rapidly stimulated LH release in healthy men (+4.4 IU/L), healthy women (+1.4 IU/L), and women with hypothalamic amenorrhea (+4.4 IU/L). Formulation stable for 60 days at 4°C.
View on PubMed →FAQs
